A Study to Investigate Safety and Effect of Sparsentan in Combination With SGLT2 Inhibition in Participants With IgAN
Trial details
- Registry ID
- NCT05856760
- Phase
- Phase 2
The FDA approved Sparsentan (Filspari) on 17 Feb 2023.
Drug identity checked against registry records
Also recorded as Filspari; RE-021
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| A Study to Investigate Safety and Effect of Sparsentan in Combination With SGLT2 Inhibition in Participants With IgANNCT05856760 | TVTX | Phase 2 | Completed | 2024-10-14Actual |
| Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular DiseasesNCT05003986 | TVTX | Phase 2 | Recruiting | 2027-03-12Estimated |
| Date as reported | Drug / company | Event | Condition | Evidence |
|---|---|---|---|---|
| 2023-02-17Day | Sparsentan | FDA original application approvalFDA approval decision | Not specified | Open original sourceRead source excerpt{"application_number": "NDA216403", "applicant_as_listed_by_fda": "TRAVERE", "brand_names": ["FILSPARI"], "active_ingredients": ["SPARSENTAN"], "submission_type": "ORIG", "submission_number": "1", "submission_status": "AP", "submission_status_date": "20230217", "matched_on": "drug name equals FDA sole active ingredient"} First seen: 06 Oct 2026 · Evidence last checked: 06 Oct 2026 |